New hope for hard-to-treat colon cancer: targeted combo enters human testing
NCT ID NCT05722327
First seen Nov 01, 2025 · Last updated Jun 07, 2026 · Updated 28 times
Summary
This early-stage trial tests a new drug called adagrasib combined with two existing cancer drugs (cetuximab and irinotecan) in people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. The main goal is to find a safe dose and check for side effects. About 24 adults who have already tried at least two other chemotherapy regimens will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.